Abstract
α- and β-glucosidases are postulated to be a very attractive therapeutic target since they catalyze the cleavage of glycosidic bonds releasing glucose from the non-reducing end of an oligo- or polysaccharide chain involved in glycoprotein biosynthesis. Glucosidase inhibitors are currently of interest owing to their promising therapeutic potential in the treatment of disorders such as diabetes, AIDS, metastatic cancer and lysosomal storage diseases. α-Glucosidases can be divided into two groups, family I and family II, and the appropriate choice of the homologue enzyme to structure-based drug design purposes could prove to be successful in the development of new pharmaceuticals. In this work, we have found the highest identity of the human enzyme with the rat intestinal sucrase, when compared to other homologue proteins commonly used in biological assays, such as Saccharomyces cerevisiae α-glucosidase. Consequently, we have built and validated a 3D model for this rat enzyme, and additionally performed docking simulations of well-known glucosidase inhibitors as well as pharmacophore modeling and molecular interaction fields studies in order to establish the most relevant structural features of inhibitors and enzyme for inhibitory activity. Using this mixed methodology we have proposed how the reported inhibitors may interact at molecular level as well as discussed the role of key α-glucosidase residues in the active site, in order to design novel proposals of inhibitors.
Keywords: α-Glucosidase, glucosidase inhibitor, structure-based drug design, ligand-based drug design
Current Bioactive Compounds
Title: Structure and Ligand-Based Drug Design to Propose Novel α-Glucosidase Inhibitors
Volume: 5 Issue: 2
Author(s): Adriane da S. Gomes, Carlos H.T.P. Silva, Vinicius B. da Silva and Ivone Carvalho
Affiliation:
Keywords: α-Glucosidase, glucosidase inhibitor, structure-based drug design, ligand-based drug design
Abstract: α- and β-glucosidases are postulated to be a very attractive therapeutic target since they catalyze the cleavage of glycosidic bonds releasing glucose from the non-reducing end of an oligo- or polysaccharide chain involved in glycoprotein biosynthesis. Glucosidase inhibitors are currently of interest owing to their promising therapeutic potential in the treatment of disorders such as diabetes, AIDS, metastatic cancer and lysosomal storage diseases. α-Glucosidases can be divided into two groups, family I and family II, and the appropriate choice of the homologue enzyme to structure-based drug design purposes could prove to be successful in the development of new pharmaceuticals. In this work, we have found the highest identity of the human enzyme with the rat intestinal sucrase, when compared to other homologue proteins commonly used in biological assays, such as Saccharomyces cerevisiae α-glucosidase. Consequently, we have built and validated a 3D model for this rat enzyme, and additionally performed docking simulations of well-known glucosidase inhibitors as well as pharmacophore modeling and molecular interaction fields studies in order to establish the most relevant structural features of inhibitors and enzyme for inhibitory activity. Using this mixed methodology we have proposed how the reported inhibitors may interact at molecular level as well as discussed the role of key α-glucosidase residues in the active site, in order to design novel proposals of inhibitors.
Export Options
About this article
Cite this article as:
Gomes da S. Adriane, Silva H.T.P. Carlos, da Silva B. Vinicius and Carvalho Ivone, Structure and Ligand-Based Drug Design to Propose Novel α-Glucosidase Inhibitors, Current Bioactive Compounds 2009; 5 (2) . https://dx.doi.org/10.2174/157340709788451984
DOI https://dx.doi.org/10.2174/157340709788451984 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy An Efficiently Sonochemical Synthesis of Novel Pyrazoles, Bipyrazoles and Pyrazol-3- ylPyrazolo[3,4-d]pyrimidines Incorporating 1H-benzoimidazole Moiety
Current Organic Chemistry Venous Thromboembolism Risk and Adequacy of Prophylaxis in High Risk Pregnancy in the Arabian Gulf
Current Vascular Pharmacology Crocin Protects Human Umbilical Vein Endothelial Cells from High Glucose-Induced Injury Via Inhibiting the Endoplasmic Reticulum Stress Response
Current Molecular Medicine Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Glycogen Phosphorylase as a Target for Type 2 Diabetes: Synthetic, Biochemical, Structural and Computational Evaluation of Novel N-acyl-N´-(<i>β</i>-D-glucopyranosyl) Urea Inhibitors
Current Topics in Medicinal Chemistry Statins as Either Immunomodulators or Anti-Cancer Drugs: Functional Activities on Tumor Stromal Cells and Natural Killer Cells
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome
Mini-Reviews in Medicinal Chemistry Electrochemical Measurement of Antidiabetic Potential of Medicinal Plants Using Screen-printed Carbon Nanotubes Electrode
Current Nanoscience Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Dyslipidaemia, Hypercoagulability and the Metabolic Syndrome
Current Vascular Pharmacology Treating Cancer and No-Cancer Pain in Older and Oldest Old Patients
Current Pharmaceutical Design Novel Glycomimetics: Anomeric and N-Glycosyl Sulfonamides
Current Organic Chemistry Effect of Glyoxal Modification on a Critical Arginine Residue (Arg-31α) of Hemoglobin: Physiological Implications of Advanced Glycated end Product an <i>in vitro</i> Study
Protein & Peptide Letters Endothelial Function and Pathogenesis of Endothelial Dysfunction
Current Immunology Reviews (Discontinued) Structure-Bioactivity Relationship Study of Xanthene Derivatives: A Brief Review
Current Organic Synthesis T-type Ca Channel Blockers in Patients with Chronic Kidney Disease in Clinical Practice
Current Hypertension Reviews The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology